Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.3191 USD
−39.86 M USD
0.00 USD
15.37 M
About Unity Biotechnology, Inc.
Sector
Industry
CEO
Anirvan Ghosh
Website
Headquarters
South San Francisco
Founded
2009
FIGI
BBG00F412FG6
Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of UBX is 1.0206 USD — it has increased by 0.03% in the past 24 hours. Watch Unity Biotechnology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Unity Biotechnology, Inc. stocks are traded under the ticker UBX.
UBX stock has fallen by −4.76% compared to the previous week, the month change is a −14.53% fall, over the last year Unity Biotechnology, Inc. has showed a −40.32% decrease.
We've gathered analysts' opinions on Unity Biotechnology, Inc. future price: according to them, UBX price has a max estimate of 8.00 USD and a min estimate of 6.00 USD. Watch UBX chart and read a more detailed Unity Biotechnology, Inc. stock forecast: see what analysts think of Unity Biotechnology, Inc. and suggest that you do with its stocks.
UBX stock is 7.22% volatile and has beta coefficient of 0.43. Track Unity Biotechnology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Unity Biotechnology, Inc. there?
Yes, you can track Unity Biotechnology, Inc. financials in yearly and quarterly reports right on TradingView.
Unity Biotechnology, Inc. is going to release the next earnings report on Mar 12, 2025. Keep track of upcoming events with our Earnings Calendar.
UBX earnings for the last quarter are −0.38 USD per share, whereas the estimation was −0.40 USD resulting in a 5.84% surprise. The estimated earnings for the next quarter are −0.39 USD per share. See more details about Unity Biotechnology, Inc. earnings.
Unity Biotechnology, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
UBX net income for the last quarter is −6.48 M USD, while the quarter before that showed −5.28 M USD of net income which accounts for −22.77% change. Track more Unity Biotechnology, Inc. financial stats to get the full picture.
No, UBX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 19.00 employees. See our rating of the largest employees — is Unity Biotechnology, Inc. on this list?
Like other stocks, UBX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Unity Biotechnology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Unity Biotechnology, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Unity Biotechnology, Inc. stock shows the sell signal. See more of Unity Biotechnology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.